Immunic Shareholders Approve Reverse Stock Split Initiative

Immunic ( (IMUX) ) has issued an announcement.

Immunic, Inc., a late-stage biotech developer of oral therapies for neurologic diseases, is led by its phase 3 multiple sclerosis candidate vidofludimus calcium and a pipeline of earlier-stage programs addressing neurodegenerative, inflammatory and autoimmune conditions. The Nasdaq-listed company aims to expand its position in neurology-focused therapeutics through these clinical assets.

On April 14, 2026, Immunic shareholders approved a reverse stock split in the range of 1-for-10 to 1-for-30, and the board subsequently set the ratio at 1-for-10. The company filed an amendment in Delaware on April 22, 2026, and the split, effective at 12:01 a.m. on April 27, 2026, will cut outstanding shares from about 136 million to 13.6 million while leaving authorized shares and par value unchanged.

Immunic said the reverse split is primarily intended to help it meet contractual obligations under a February 12, 2026 securities purchase agreement with institutional and accredited investors. The action will affect all shareholders uniformly, with fractional positions aggregated and sold on the open market, and investors receiving cash in lieu of fractional shares; all options, warrants and similar securities will be proportionally adjusted.

The most recent analyst rating on (IMUX) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.

Spark’s Take on IMUX Stock

According to Spark, TipRanks’ AI Analyst, IMUX is a Neutral.

The score is held down primarily by weak financial performance (no revenue, large losses, and persistent cash burn with negative equity). Offsetting this, corporate events are constructive (Nasdaq compliance regained and substantial financing), while technicals are mixed and valuation metrics are unfavorable due to ongoing losses and no dividend.

To see Spark’s full report on IMUX stock, click here.

More about Immunic

Immunic, Inc. is a late-stage biotechnology company focused on developing novel oral therapies for neurologic diseases. Its lead candidate, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, following positive phase 2 data in multiple sclerosis and other indications.

The company is also advancing earlier-stage programs IMU-856 and IMU-381 to build a broader platform targeting neurodegenerative, chronic inflammatory and autoimmune-related diseases. Immunic’s shares trade on the Nasdaq Capital Market under the ticker IMUX.

Average Trading Volume: 3,810,259

Technical Sentiment Signal: Sell

Current Market Cap: $117.5M

For a thorough assessment of IMUX stock, go to TipRanks’ Stock Analysis page.